Earlier coverage reported Q3 sales rose 4% from a year earlier. DocGo still expects an adjusted loss of $17 million to $22 million in 2026, and gives no reason for the CEO transition, so the facts do not point clearly one way.
Earlier coverage said Q3 sales rose 4% from a year earlier, which points to growth. DocGo also expects an adjusted loss in 2026, and the release gives no reason for the CEO transition. These facts do not point clearly in one direction.
Follow DocGo (DCGO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for DCGO